Company intelligence / Profile preview

Gimv

Ownership: Private
Development stage: Other

Overview

Gimv is a leading European private equity and venture capital firm with over 40 years’ experience investing in innovative life science and healthcare companies. It recently established a dedicated Life Sciences platform focused on drug development, medtech, digital health, life science tools, and agro-biotechnology. Its investments span early preclinical to late-stage clinical programs through partnerships with high-growth potential firms.

Therapeutic areas: ImmunologyOncology
Modalities: Small molecule (via portfolio companies)Monoclonal antibody (via portfolio companies)Radiopharmaceutical (via portfolio companies)Protein therapeutics (via portfolio companies)
Industry: Investors

Partnerships

Biotech Fonds Vlaanderen (co-investor)Edmond de Rothschild Investment Partners (co-investor)Johnson & Johnson (via portfolio company acquisition, e.g., Covagen)

Beyond the preview

Go deeper on Gimv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gimv.

Explore the full profile